Illumina Selected as Preferred Service Provider for Cancer Research UK | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina today announced it has been selected as a preferred service provider for Cancer Research UK.

As a result, Illumina will provide a range of services, starting with whole genome sequencing, to support the International Cancer Genome Consortium, which aims to develop a comprehensive description of genomic, transcriptomic, and epigenomic changes in 50 different tumor types and/or subtypes of clinical and societal importance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

BGI CEO Ye Yin says that mapping variation within the human genome will bring a "big data revolution" to healthcare, Wired UK writes.

All the images that investigators produce through their research present a challenge to share, Nature News reports.

The House of Representatives science committee has approved a measure that includes new rules for large National Science Foundation projects, ScienceInsider reports.

In PLOS this week: founder mutation linked to some leukoencephalopathy cases, transcript and protein profiles of the kissing bug, and more.